Evaluation of vaccines effective against coronavirus
Notice bibliographique
Résumé
Given the COVID-19 virus epidemic and vaccination increment all around the world, after surveying the vaccination side effects it was clarified that 72.6% of individuals reported at least one symptom after the first and second injection of Pfizer-BioNTech vaccine which pain at injection site, fever and myalgia/arthralgia were most common among these symptoms. Furthermore, most common severe side effects like fever > 39 °C were perceived more after the second dose of vaccine. In the study of identifying body’s physiologic changed, heart rate variability (HRV) decreased after the first dose and the second dose without having considerable changes in resting heart rate (RHR) and respiratory rate (RR) and the duration of sleep also declined up to 4 days of both vaccination doses. Plus, Local and systemic reactogenicity were more intense after the second dose. Following the COVID-19 vaccination, various allergic reactions also started to promote all around the countries, a questionnaire was adjusted in Toronto-Canada and 65 patients had PEG-ASNase allergy. Rapid reactions like anaphylaxis occur following the first dose of Pfizer mRNA COVID-19 vaccine. In a study consisted of 175 individuals, 21 of them were afflicted with anaphylaxis and a number of 83 individuals experienced non-anaphylaxis allergic reactions but still further studies are required in order to identify the relation between anaphylaxis and COVID-19 vaccines. Disease background is an outstanding factor to intensify COVID-19 infection. In a research, a 40-year old woman who had experienced left peripheral facial nerve palsy 4 years ago and in another research 8 adolescents who visited Nicklaus Children’s Hospital with perimyocarditis within 4 days of receiving the second dose of BNT162b2 vaccine, were investigated in this context. In terms of gender and age relation, a study was carried out on German residents of Bavaria between Jan 9 to Apr 11, 2021 and, it was clarified that both doses of the BioNTech-Pfizer’s BNT162b2 are highly effective against the infection and adverse events of COVID-19 virus in elder people and according to another report, 82% of individuals experienced at least one symptom Following the first dose of Comirnaty vaccine which was more common in women under the age 55 (64%). In a study which was carried out among the workers of Mazandaran University of Medical Sciences in order to identify the side effects of the Sputnik V vaccine, a number of 3236 individuals in the 19-78 age range with the mean age of 38 years old submitted their report. According to a research which was conducted in Bavaria, Germany, the mortality rate was considerably lower in individuals who had received vaccination in relation to not vaccinated individuals, however, 3 death cases were reported in individuals who suffered from comorbidities after receiving the Sputnik vaccine which was considered to be irrelevant to vaccination. A research was conducted to evaluate the effectiveness of Robust antibody after the first and second dose in individuals aged between 70 and 90. From 99 individuals who received the first dose of their vaccination after 3 weeks the existence of Robust antibody was proven in 95% of them and from 86 individuals who received their vaccine’s second dose after 3 weeks, all of them showed a positive result in the test. Furthermore, in another study from 75% of old individuals who were vaccinated at least once, the first dose led into COVID-19 infection decrease and had an effectiveness of 52% in clinical experiments. According to another report, the antibody was observed in 92% of individuals 21 days after the first dose and also in 97% of them 21 days after the second dose it was concluded that Symptoms following vaccination are not unusual and they occur because of body’s immune system response.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,109 | 0,012 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,003 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; les deux têtes enseignantes s’accordent sur ce qui est montré ici.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».